These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk]. Bijlsma JW Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407 [TBL] [Abstract][Full Text] [Related]
6. FDA announces changes affecting the marketing of non-steroidal anti-inflammatory drugs. FDA Consum; 2005; 39(3):7. PubMed ID: 16127812 [No Abstract] [Full Text] [Related]
7. Cyclooxygenase-2 inhibitors and cardiovascular risk. Smith ER Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124 [No Abstract] [Full Text] [Related]
8. [COX-2 inhibitors--one step forward and two steps back]. Evensen S; Spigset O; Slørdal L Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733 [TBL] [Abstract][Full Text] [Related]
9. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor. Mukherjee D Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915 [TBL] [Abstract][Full Text] [Related]
10. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases]. Guo ZR Yao Xue Xue Bao; 2005 Nov; 40(11):967-9. PubMed ID: 16499077 [No Abstract] [Full Text] [Related]
11. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall]. Meyer CH Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404 [No Abstract] [Full Text] [Related]
12. [Mefloquine: neuropsychiatric adverse effects are often severe and persistent long after withdrawal of the drug]. Jensen JJ Ugeskr Laeger; 1998 Apr; 160(16):2413. PubMed ID: 9616091 [No Abstract] [Full Text] [Related]
13. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. Jugdutt BI Circulation; 2007 Jan; 115(3):288-91. PubMed ID: 17242292 [No Abstract] [Full Text] [Related]
14. COX-2 inhibitors and the heart: putting risk in perspective. Bobadilla RV; Barnett EM; Randels CL Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003 [No Abstract] [Full Text] [Related]
15. The COX-2 inhibitors--an update. Furberg CD Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896 [No Abstract] [Full Text] [Related]
16. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? Messerli FH; Sichrovsky T Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380 [No Abstract] [Full Text] [Related]
17. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen. Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752 [No Abstract] [Full Text] [Related]
18. Neuropsychiatric disorders during intranasal corticosteroid therapy. Mansfield LE Ann Allergy Asthma Immunol; 2008 Sep; 101(3):333-4. PubMed ID: 18814458 [No Abstract] [Full Text] [Related]
19. Vioxx withdrawal alarms cancer prevention researchers. Vanchieri C J Natl Cancer Inst; 2004 Dec; 96(23):1734-5. PubMed ID: 15572751 [No Abstract] [Full Text] [Related]
20. Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Couzin J Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414 [No Abstract] [Full Text] [Related] [Next] [New Search]